- |||||||||| Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal: Thiazolidinedione use and retinal fluid in the comparison of age-related macular degeneration treatments trials. (Pubmed Central) - Apr 19, 2022 P3 In this exploratory analysis, patients with diabetes taking thiazolidinediones and treated with bevacizumab or ranibizumab for nAMD had worse baseline mean VA, greater reductions in subretinal and subretinal tissue complex thickness from baseline, and greater proportions with IRF comparing to patients not taking thiazolidinediones.
- |||||||||| zifibancimig (RG6120) / Roche
Enrollment change: BURGUNDY: Study of Zifibancimig in Participants With Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - Apr 15, 2022 P1, N=190, Recruiting, In this exploratory analysis, patients with diabetes taking thiazolidinediones and treated with bevacizumab or ranibizumab for nAMD had worse baseline mean VA, greater reductions in subretinal and subretinal tissue complex thickness from baseline, and greater proportions with IRF comparing to patients not taking thiazolidinediones. N=50 --> 190
- |||||||||| Razumab (ranibizumab biosimilar) / Intas, Lucentis (ranibizumab) / Roche, Novartis
Journal, HEOR, Real-world evidence: Innovator Versus Biosimilar Ranibizumab in Polypoidal Choroidal Vasculopathy: Real-World Evidence. (Pubmed Central) - Apr 13, 2022 Our real-world data demonstrated the ranibizumab biosimilar Razumab to have comparable visual acuity outcomes to the innovator ranibizumab molecule with an adequate safety profile in the management of PCV. Although these encouraging results support its use as a viable alternative to the innovator molecule, further prospective studies in a diverse patient population are needed to validate our findings.
- |||||||||| Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron
Journal: Bevacizumab for blinding eye disease - is it time for the PBS to list for off-label use? (Pubmed Central) - Apr 12, 2022 Legislation for this approach has been approved in France, the UK, and Italy. Only by eliminating the legal risk to authorising bodies and physicians, and the financial disincentive to the patient associated with off-label use, will drugs such as bevacizumab be more widely adopted.
- |||||||||| Susvimo (ranibizumab port delivery system) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Trial completion date: Pagoda: A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Subtudy to Evaluate the Safety of Re-Implanting the PDS With Ranibizumab in Participants With DME (clinicaltrials.gov) - Apr 12, 2022 P3, N=545, Active, not recruiting, Only by eliminating the legal risk to authorising bodies and physicians, and the financial disincentive to the patient associated with off-label use, will drugs such as bevacizumab be more widely adopted. Trial completion date: Sep 2024 --> Feb 2024
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Review, Journal: Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis. (Pubmed Central) - Apr 10, 2022 Significantly fewer ranibizumab injections were administered in the T&E arm at one (MD -2.42 injections, p < 0.0001) and two years (MD -6.06 injections, p < 0.00001) relative to fixed dosing...Low-certainty evidence from the present synthesis implies that T&E preserves VA similar to fixed schedules with significantly fewer injections at one and two years. Also, patients with T&E dosing achieved better VA outcomes than those on PRN regimen but T&E dosing was associated with more injections.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Journal: Ten-year survival trends of neovascular age-related macular degeneration at first presentation. (Pubmed Central) - Apr 9, 2022 Our analyses suggest that one in five patients will retain good vision (BCVA ≥70 ETDRS letters) in the first-affected eye at 10 years after starting anti-VEGF treatment; yet, one in two patients will have good vision in their better-seeing eye. Moreover, our data suggest that early treatment of nAMD is associated with better visual outcomes.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Journal: Vascular endothelial growth factor-A level in human breast milk after intravitreal injection of ranibizumab: a case report. (Pubmed Central) - Apr 8, 2022 The concentration of vascular endothelial growth factor-A in human breast milk of a mother who continues lactating dropped initially and rose to pre-injection level about 24 h after intravitreal injection of ranibizumab. The data may offer more information to evaluate the impact of anti-vascular endothelial growth factor agent intravitreal injection of lactating mothers and their breastfed infants.
- |||||||||| Avastin (bevacizumab) / Roche
Clinical guideline, Review, Journal: A systematic review of clinical practice guidelines for myopic macular degeneration. (Pubmed Central) - Apr 7, 2022 Intravitreal injection of anti-VEGF agents was recommended as an effective intervention to treat myopic CNV as the first-line treatment, while there was inadequate guidance for the application of PDT in myopic CNV management. The use of other interventions for MMD were not recommended at this time and additional evidence is called for.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Trial completion date: MERIT: Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial (clinicaltrials.gov) - Apr 1, 2022 P3, N=194, Completed, We provide real world data suggesting a sustained anatomical and functional benefit of switching from ranibizumab to aflibercept in the treatment of refractory DMO. Recruiting --> Completed | Trial completion date: Jul 2022 --> Feb 2022
- |||||||||| Avastin (bevacizumab) / Roche
Review, Journal: Anti-VEGF Crunch Syndrome in Proliferative Diabetic Retinopathy: A Review. (Pubmed Central) - Mar 31, 2022 Our review found that intravitreal anti-VEGF, in particular bevacizumab, should be used with caution when treating patients with severe proliferative diabetic retinopathy and pre-existing intraocular fibrosis...The existing literature on the anti-VEGF crunch is limited by heterogeneity in the way crunch is documented and characterized and the presence of PRP as a confounding factor. Because of these methodological flaws, the relative frequency of the anti-VEGF crunch cannot be accurately estimated.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Journal: Design of a Novel Fab-Like Antibody Fragment with Enhanced Stability and Affinity for Clinical use. (Pubmed Central) - Mar 26, 2022 The high-resolution crystal structures of m912 FabCH3 and m912 Fab are determined, and the comparative analysis reveals more rigid structures in both constant domains and complementarity-determining regions of FabCH3, explaining its enhanced stability and affinity. Overall, the stabilized FabCH3 described in this report provides a versatile platform for engineering Fab-like antibody fragments with higher stability and antigen-binding affinity that can be used as a distinct class of antibody therapeutics.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Journal, HEOR: Relationship between stereopsis and vision-related quality of life in patients with branch retinal vein occlusion. (Pubmed Central) - Mar 25, 2022 To investigate the relationship between stereopsis and vision-related quality of life (VR-QOL) in patients with branch retinal vein occlusion (BRVO) before and after treatment with intravitreal ranibizumab (IVR)...Treatment with IVR for BRVO improved cystoid macular oedema, which was correlated to improved stereopsis, although not to the control level. The TNO score at baseline was associated with VR-QOL in patients with BRVO.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Trial completion date, Trial primary completion date: Analysis of na (clinicaltrials.gov) - Mar 21, 2022 P=N/A, N=34, Completed, Widefield OCT angiography showed a decrease of RCNPA after IRI, probably related to the reperfusion of retinal capillaries. Recruiting --> Completed | Trial completion date: Dec 2021 --> Sep 2021 | Trial primary completion date: Dec 2021 --> Sep 2021
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Biotech
Clinical, Journal: Effects of Anti-Vascular Endothelial Growth Factor Drugs Before and After Pars Plana Vitrectomy in Patients with Polypoidal Choroidal Vasculopathy and Vitreous Hemorrhage. (Pubmed Central) - Mar 17, 2022 Compared with the postoperative group, the perioperative group had thinner fovea at 1 week, 1 month, and 3 months (P < 0.05), but the differences disappeared after 3 months. In patients with PCV and vitreous hemorrhage, compared with postoperative anti-VEGF, perioperative anti-VEGF could reduce the difficulty of surgery and reduce the occurrence of postoperative complications, but there were no differences in long-term vision and macular thickness after surgery.
- |||||||||| Visanne (dienogest) / Mochida, Bayer, Lucentis (ranibizumab) / Roche, Novartis
Preclinical, Journal: Effects of ranibizumab and zoledronic acid on endometriosis in a rat model. (Pubmed Central) - Mar 16, 2022 In patients with PCV and vitreous hemorrhage, compared with postoperative anti-VEGF, perioperative anti-VEGF could reduce the difficulty of surgery and reduce the occurrence of postoperative complications, but there were no differences in long-term vision and macular thickness after surgery. According to these results, zoledronic acid and ranibizumab may be putative candidates for the treatment of endometriosis.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Review, Journal: An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review. (Pubmed Central) - Mar 15, 2022 Several biosimilar candidates of ranibizumab and aflibercept are currently in development and the first biosimilar of ranibizumab received EMA approval in August and FDA approval in September 2021...Biosimilars have been used successfully across a wide range of therapeutic areas for the past 15 years where they have achieved substantial cost savings that can be reinvested into healthcare systems without affecting the quality of patient care. The current review provides an introduction to biosimilars with the aim of preparing retinal specialists for discussing these products with their patients.
|